Roche, Trimeris withdraw application for Fuzeon injection device

10/3/2007 | News & Observer (Raleigh, N.C.), The · Forbes

Roche Holding subsidiary Hoffmann-La Roche and Trimeris said they are withdrawing their FDA application to market the Biojector 2000 needle-free injection device in combination with HIV drug Fuzeon, following a comprehensive evaluation of a clinical trial and a delay in getting regulatory approval. The companies believe the device isn't an ideal substitute for the delivery of the drug among "all treatment-experienced patients" despite its potential benefits, a Roche official said.

View Full Article in:

News & Observer (Raleigh, N.C.), The · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN